Eli Lilly vs Johnson & Johnson — CEO Pay Comparison
David Ricks (Eli Lilly) earns $3.0M more in total compensation than Joaquin Duato (Johnson & Johnson).
| Metric | Eli LillyLLY | Johnson & JohnsonJNJ |
|---|---|---|
| CEO | David Ricks | Joaquin Duato |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Total Compensation | $15.0M | $12.0M |
| Base Salary | $1.5M | $1.2M |
| Stock Awards | $7.5M | $6.0M |
| Option Awards | $1.8M | $1.4M |
| Non-Equity Incentive | $2.3M | $1.8M |
| Pay-for-Performance Grade | A (94/100) | B (68/100) |
| CEO-Worker Pay Ratio | 150:1 | 120:1 |
| Median Worker Pay | $100K | $100K |
| Say-on-Pay Approval | 87.9% | 94.8% |
| 3yr Total Shareholder Return | +66.7% | +1.4% |
| Revenue | $41.3B | $85.2B |
| Market Cap | $800.0B | $370.0B |
| Employees | 43,000 | 131,900 |
Analysis
David Ricks (Eli Lilly) earns $15.0M in total compensation, while Joaquin Duato (Johnson & Johnson) earns $12.0M. That is a difference of $3.0M.
On pay-for-performance alignment, Eli Lilly scores A (94/100) while Johnson & Johnson scores B (68/100). Eli Lilly's CEO compensation is better aligned with company performance.
Eli Lilly's CEO-to-worker pay ratio is 150:1 compared to Johnson & Johnson's 120:1. Shareholders approved CEO pay at 87.9% (Eli Lilly) and 94.8% (Johnson & Johnson).